• Mai Shimada, MD

This week in ketamine 9/20





Drugs Effects of Ketamine in Mice can Depend on the Sex of the Human Experimenter


More:

  • Researchers at the University of Maryland School of Medicine have shown that mice respond more to the antidepressant effects of the drug ketamine when administered by men and not by women.

  • When the researchers had women administer the ketamine along with an injection of CRF, the mice finally responded to ketamine as if they were being treated with an antidepressant

  • People do not respond well to ketamine antidepressant therapy might respond if we could administer the treatment with some CRF-related chemical that could induce ketamine’s effects


  1. A retrospective chart reviews with more than 400 participants with TRD suggests Ketamine infusions can help reduce symptoms of suicidal ideation, depression, and anxiety in patients with treatment-resistant depression (TRD).

More:

  • Results from a retrospective chart review analysis, which included more than 400 participants with TRD, illustrate that ketamine is a safe and rapid treatment in a real-world patient population

  • Response and remission rates were 72% and 38%, respectively, after 10 infusions, and there was a 50% reduction in self-harm/suicidal ideation (SI) symptom scores within 6 weeks.

  • Half of patients with SI at baseline no longer had it after 6 infusions.

  • A 30% reduction in anxiety symptoms (per the GAD-7) was observed.



PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease


More:

  • Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at the MDS International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

  • Ketamine was safe and well-tolerated with 100% of patients treated with ketamine demonstrating a reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS).

  • UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003), 49% at 3-week (p=0.006) and 41% at 3-month (p=0.011) post-ketamine.

  • Planning a Phase 3 clinical study to allow for FDA approval of KETARX (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway

  • The study enrolled 10 subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr.




NHS spending watchdog rejects ketamine nasal spray for depression as psychiatrists accuse NICE of 'discrimination' against mental health patients - after EU approves £1,000-a-week drug


More:

  • EU Medicines Agency approved a ketamine treatment for depression in 2019

  • But UK regulator NICE rejected esketamine nasal spray costing £489 per dose

  • They had concerns the drug Spravato had to be given in hospital twice a week

  • Drug firm Janssen, backed by Royal College of Psychiatrists, appealed decision

  • Royal College accused NICE of 'discrimination' against mental health patients

  • NICE’s appraisal committee will reconvene in October to explain its rationale and discuss which clinical uncertainties linked to mental illness are



We'll discuss these topics in our webinar on Thursday.

Sign up from here👉 https://www.meetup.com/ketamine-assisted-therapy-kap-group-with-isha/events/288596564/

9 views0 comments

Recent Posts

See All